Suppr超能文献

奥地利阿片类药物和非阿片类药物处方趋势(2016 - 2021年):一项关于使用情况及苯二氮䓬类药物联合使用的全国性研究

Trends in Opioid and Non-opioid Prescriptions in Austria (2016-2021): A Nationwide Study on Utilization and Concomitant Benzodiazepine Use.

作者信息

Bilir Aylin, Kapral Lorenz, Michalek-Sauberer Andrea, Bologheanu Razvan, Gruber Felix, Kimberger Oliver

机构信息

Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Clinical Division of General Anaesthesia and Intensive Care Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Ludwig Boltzmann Institute Digital Health and Patient Safety, Waehringer Guertel 104/10, 1180, Vienna, Austria.

出版信息

Pain Ther. 2025 Jun;14(3):1131-1145. doi: 10.1007/s40122-025-00736-4. Epub 2025 May 5.

Abstract

INTRODUCTION

Although global opioid consumption is decreasing, high-income populations are experiencing an increase. Data on specific opioid-prescribed and at-risk patient groups in Austria are lacking.

METHODS

We performed a retrospective observational population-based study analysing health insurance data between January 2016 and December 2021. The dataset included demographic information; hospital data, including coded primary and secondary discharge diagnoses; and prescription data for all legally available opioids and nonopioid analgesics. The primary objective was to describe trends in opioid and nonopioid analgesic prescriptions. Logistic regression analysis was conducted to identify potential risk factors for receiving an opioid prescription.

RESULTS

The study cohort included 7,274,651 individuals. During the observation period, the percentage of individuals receiving an opioid prescription decreased by 14.69% (4.22-3.60%). The number of individuals receiving an opioid prescription was consistently greatest for tramadol. A particularly strong positive correlation was observed between opioid prescriptions and the concurrent use of benzodiazepines (odds ratio [OR], 1.45 [95% confidence interval {CI}, 1.43-1.47]). Furthermore, a history of persistent somatoform pain disorder (OR, 1.28 [95% CI, 1.21-1.36]) and a diagnosis of pain disorder (OR, 1.26 [95% CI, 1.25-1.28]) were identified as significant risk factors. In 2021, general practitioners were the predominant initial opioid prescribers, issuing 82.17% of the prescriptions, followed by hospital staff and orthopaedic specialists.

CONCLUSION

Prescription opioid use decreased from 2016 to 2021, with tramadol representing the most prevalent opioid. The study revealed a strong link between opioid and benzodiazepine prescriptions and an association with persistent somatoform pain disorder, where opioid use is typically not recommended. Interactive map available for this article.

摘要

引言

尽管全球阿片类药物消费量在下降,但高收入人群的消费量却在增加。奥地利缺乏关于特定阿片类药物处方和高危患者群体的数据。

方法

我们进行了一项基于人群的回顾性观察研究,分析了2016年1月至2021年12月期间的健康保险数据。数据集包括人口统计学信息;医院数据,包括编码的主要和次要出院诊断;以及所有合法可用阿片类药物和非阿片类镇痛药的处方数据。主要目的是描述阿片类药物和非阿片类镇痛药处方的趋势。进行逻辑回归分析以确定接受阿片类药物处方的潜在风险因素。

结果

研究队列包括7274651人。在观察期内,接受阿片类药物处方的个体百分比下降了14.69%(4.22 - 3.60%)。接受曲马多阿片类药物处方的个体数量一直最多。在阿片类药物处方与同时使用苯二氮䓬类药物之间观察到特别强的正相关(比值比[OR],1.45[95%置信区间{CI},1.43 - 1.47])。此外,持续性躯体形式疼痛障碍病史(OR,1.28[95%CI,1.21 - 1.36])和疼痛障碍诊断(OR,1.26[95%CI,1.25 - 1.28])被确定为显著风险因素。2021年,全科医生是主要的初始阿片类药物开方者,开出了82.17%的处方,其次是医院工作人员和骨科专家。

结论

2016年至2021年期间,处方阿片类药物的使用有所下降,曲马多是最普遍使用的阿片类药物。该研究揭示了阿片类药物与苯二氮䓬类药物处方之间的紧密联系以及与持续性躯体形式疼痛障碍的关联,而持续性躯体形式疼痛障碍通常不建议使用阿片类药物。本文提供交互式地图。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ae1/12085738/3a29dd8c7e95/40122_2025_736_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验